Evidence map›Paper›PMID 42816507›Full record

ArticleNature communications2026

ERα Micromap (µMap) proximity labeling reveals fulvestrant mechanisms.

Chun Li, Zihan Dong, Romain O Georges, Kristina Danga, Ciaran P Seath, Yuka Amako, Jack L Sloane, Aya M Kelly, Joel W Thompson, David W C MacMillan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chun Li *Merck Center for Catalysis at Princeton University, Princeton, NJ, USA.
Zihan Dong *Merck Center for Catalysis at Princeton University, Princeton, NJ, USA.
Romain O GeorgesBristol Myers Squibb, San Diego, CA, USA.
Kristina DangaBristol Myers Squibb, San Diego, CA, USA.
Ciaran P SeathMerck Center for Catalysis at Princeton University, Princeton, NJ, USA.ORCID 0000-0002-6774-128X
Yuka AmakoBristol Myers Squibb, Cambridge, MA, USA.
Jack L SloaneBristol Myers Squibb, Cambridge, MA, USA.
Aya M KellyBristol Myers Squibb, Cambridge, MA, USA.
Joel W ThompsonBristol Myers Squibb, San Diego, CA, USA. joel.thompson@bms.com.ORCID 0000-0002-5131-3248
David W C MacMillanMerck Center for Catalysis at Princeton University, Princeton, NJ, USA. dmacmill@princeton.edu.ORCID 0000-0001-6447-0587

Funding

BD FACSymphony A3: A multi-laser analytical flow cytometer for the Princeton University Flow Cytometry Resource FacilityS10OD028592 · OD · PRINCETON UNIVERSITY · PI DECOSTE, CHRISTINA J. · 2021 to 2021
$400k
NIH HHS S10 OD028592
6 · The paper itself

Abstract

Estrogen Receptor alpha (ERα) is the primary driver in ER+ breast cancer and can be targeted using small molecules such as fulvestrant, a selective estrogen receptor degrader (SERD). Despite being approved over two decades ago and used regularly in post-menopausal women, its precise anti-tumor mechanism remains unclear, with several reports showing efficacy without the requirement for ERα degradation. To investigate the molecular basis of fulvestrant's action, we employed split intein-based µMap photo-proximity labeling to profile ERα-associated interactions. Our findings reveal that fulvestrant displaces oncogenic interactions induced by estradiol and promotes ERα translocation to promyelocytic leukemia (PML) nuclear bodies, leading to altered transcriptional signatures and senescence. Overall, this study offers insights into SERD mechanism of action and establishes a framework for evaluating additional ERα modulators and degraders.

Indexed as

Breast NeoplasmsEstrogen Receptor alphaFulvestrantCell Line, TumorEstradiolFemaleHumansMCF-7 CellsESR1 protein, humanEstradiolEstrogen Receptor alphaFulvestrant

Identifiers

PMID42816507
PMCPMC13627678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.